A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by Lotus Pharmaceutical.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Lotus Pharmaceutical
ClinicalTrials.gov Identifier:
NCT01245166
First received: November 19, 2010
Last updated: NA
Last verified: November 2010
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2011
  Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
No publications provided by Lotus Pharmaceutical

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):